Targeted Molecular Diagnostics’s (TMD) KRAS Mutation assay (DxS Diagnostics), utilizes SNP-based Real-Time PCR technology to identify seven of the most common KRAS mutations in DNA from frozen or formalin fixed paraffin embedded (FFPE) tumor specimens.
The company is said to have selected a Real-Time PCR platform to overcome the sensitivity concerns associated with sequencing technologies that have been reported in the literature. The results of the assay are available within eight to 10 days from receipt of the specimen at TMD. TMD provides specimen collection kits for convenient collection and shipment of specimens.
TMD’s KRAS Mutation assay may help identify patients who harbor specific KRAS mutations and therefore may not respond to EGFR inhibitors.